Annals of Surgical Oncology

, Volume 23, Issue 3, pp 1026–1033 | Cite as

Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma

  • Daniel P. Nussbaum
  • Mohamed A. Adam
  • Linda M. Youngwirth
  • Asvin M. Ganapathi
  • Sanziana A. Roman
  • Douglas S. Tyler
  • Julie A. Sosa
  • Dan G. BlazerIII
Pancreatic Tumors

Abstract

Background

The modifiable variable best proven to improve survival after resection of pancreatic adenocarcinoma is the addition of adjuvant chemotherapy. A theoretical advantage of minimally invasive pancreaticoduodenectomy (MI-PD) is the potential for greater use and earlier initiation of adjuvant therapy, but this benefit remains unproven.

Methods

The 2010–2012 National Cancer Data Base (NCDB) was queried for patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. Subjects were classified as MI-PD versus open pancreaticoduodenectomy (O-PD). Baseline variables were compared between groups. The independent effect of surgical approach on the use and timing of adjuvant chemotherapy was estimated using multivariable regression analyses.

Results

For this study, 7967 subjects were identified: 1191 MI-PD (14.9 %) and 6776 O-PD (85.1 %) patients. Patients who underwent MI-PD were more likely to have been treated at academic hospitals. Otherwise, the groups had no baseline differences. In both the MI-PD and O-PD groups, approximately 50 % of the patients received adjuvant chemotherapy, initiated at a median of 54 versus 55 days postoperatively (p = 0.08). After multivariable adjustment, surgical approach was not independently associated with use (odds ratio 1.00; p = 0.99) or time to initiation of adjuvant chemotherapy (–2.3 days; p = 0.07). Younger age, insured status, lower comorbidity score, higher tumor stage, and the presence of lymph node metastases were independently associated with the use of adjuvant chemotherapy.

Conclusions

At a national level, MI-PD does not result in greater use or earlier initiation of adjuvant chemotherapy. As surgeons and institutions continue to gain experience with this complex procedure, it will be important to revisit this benchmark as a justification for its increasing use for patients with pancreatic cancer.

Supplementary material

10434_2015_4937_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc. 1994;8:408–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Cuschieri A. Laparoscopic pancreatic resections. Semin Laparosc Surg. 1996;3:15–20.PubMedGoogle Scholar
  3. 3.
    Uyama I, Ogiwara H, Iida S, Takahara T, Furuta T, Kikuchi K. Laparoscopic minilaparotomy pancreaticoduodenectomy with lymphadenectomy using an abdominal wall-lift method. Surg Laparosc Endosc. 1996;6:405–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Kendrick ML, Cusati D. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg. 2010;145:19–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Palanivelu C, Jani K, Senthilnathan P, Parthasarathi R, Rajapandian S, Madhankumar MV. Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg. 2007;205:222–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Dulucq JL, Wintringer P, Mahajna A. Laparoscopic pancreaticoduodenectomy for benign and malignant diseases. Surg Endosc. 2006;20:1045–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Pugliese R, Scandroglio I, Sansonna F, et al. Laparoscopic pancreaticoduodenectomy: a retrospective review of 19 cases. Surg Laparosc Endosc Percutan Tech. 2008;18:13–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Zureikat AH, Moser AJ, Boone BA, Bartlett DL, Zenati M, Zeh HJ III. 250 Robotic pancreatic resections: safety and feasibility. Ann Surg. 2013;258:554–9; discussion 559–62.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Croome KP, Farnell MB, Que FG, et al. Pancreaticoduodenectomy with major vascular resection: a comparison of laparoscopic versus open approaches. J Gastrointest Surg. 2015;19:189–94; discussion 194.CrossRefPubMedGoogle Scholar
  10. 10.
    Kendrick ML, Sclabas GM. Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB. 2011;13:454–8.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Boone BA, Zenati M, Hogg ME, et al. Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve. JAMA Surg. 2015;150(5):416–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14:e476–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Croome KP, Farnell MB, Que FG, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg. 2014;260:633–8; discussion 638–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Adam MA, Roman SA, Sosa JA, all c. Minimally invasive versus open pancreaticoduodenectomy for cancer is associated with increased 30-day mortality. Ann Surg. 2015.Google Scholar
  15. 15.
    Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.PubMedGoogle Scholar
  16. 16.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.CrossRefPubMedGoogle Scholar
  17. 17.
    Shaib Y, Davila J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am J Gastroenterol. 2007;102:1377–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013;258:336–46.CrossRefPubMedGoogle Scholar
  20. 20.
    Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.CrossRefPubMedGoogle Scholar
  21. 21.
    Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  25. 25.
    ClinicalTrials.gov. Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the “Apact” Study) (apact), 2015. https://clinicaltrials.gov/ct2/show/NCT01964430. Accessed 2 Apr 2015.
  26. 26.
    ClinicalTrials.gov. Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma, 2015. Retrieved 2 April 2015 at https://clinicaltrials.gov/ct2/show/NCT01526135. Accessed 2 Apr 2015.
  27. 27.
    Quaresma M, Coleman MP, Rachet B. 40-Year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385(9974):1206–18.CrossRefPubMedGoogle Scholar
  28. 28.
    Kendrick ML. Laparoscopic and robotic resection for pancreatic cancer. Cancer J. 2012;18:571–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Zenoni SA, Arnoletti JP, de la Fuente SG. Recent developments in surgery: minimally invasive approaches for patients requiring pancreaticoduodenectomy. JAMA Surg. 2013;148:1154–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. Ann Surg. 2014;260:244–51.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Sutton JM, Wilson GC, Wima K, et al. Readmission after pancreaticoduodenectomy: the influence of the volume effect beyond mortality. Ann Surg Oncol. 2015;22(12):3785–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227–34.CrossRefPubMedGoogle Scholar
  34. 34.
    Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer. 2010;116:1681–90.CrossRefPubMedGoogle Scholar
  35. 35.
    Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–75.CrossRefPubMedGoogle Scholar
  38. 38.
    Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–12.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Daniel P. Nussbaum
    • 1
  • Mohamed A. Adam
    • 1
  • Linda M. Youngwirth
    • 1
  • Asvin M. Ganapathi
    • 1
  • Sanziana A. Roman
    • 1
  • Douglas S. Tyler
    • 2
  • Julie A. Sosa
    • 1
  • Dan G. BlazerIII
    • 1
  1. 1.Department of SurgeryDuke UniversityDurhamUSA
  2. 2.Department of SurgeryThe University of Texas Medical BranchGalvestonUSA

Personalised recommendations